Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

RBC Capital Downgrades Avidity Biosciences to Sector Perform, Raises Price Target to $72

Author: Benzinga Newsdesk | October 28, 2025 05:18am
RBC Capital analyst Luca Issi downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Sector Perform and raises the price target from $61 to $72.

Posted In: RNA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist